exoIL 12
Alternative Names: CDK-003; exoIL-12; exoInterleukin-12Latest Information Update: 28 Oct 2023
At a glance
- Originator Codiak BioSciences
- Class Antineoplastics; Exosome therapies; Gene therapies; Immunotherapies; Interleukins
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cutaneous T-cell lymphoma
- No development reported Solid tumours
- Discontinued Infections
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Cutaneous-T-cell-lymphoma(In volunteers) in United Kingdom (SC, Injection)
- 28 May 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intratumoural, Injection)
- 30 Aug 2022 Codiak BioSciences terminates a phase I/IIa trial in Cutaneous T-cell lymphoma (Second-line therapy or greater) in United Kingdom (Intralesional) due to early positive results (NCT05156229)